Search Results

Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience.

Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.

Aptinyx’s NYX-458 fell short of the primary endpoint in a Phase II trial of patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

Aptinyx Inc. today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.

Aptinyx Inc. (Nasdaq: APTX) today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.

Aptinyx Inc. today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.

Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference.

Aptinyx Inc. (Nasdaq: APTX), today reported financial results for the second quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.